How VIJOICE May Help

VIJOICE® (alpelisib) tablets

VIJOICE is the first and only therapy approved to treat the cause of PROS in children and adults

The safety and effectiveness of VIJOICE® (alpelisib) tablets were studied in 57 adults and children aged 2 years and older with CLOVES syndrome, MCAP or M-CM, KTS, FIL, and 2 people with unspecified PIK3CA-Related Overgrowth Spectrum, or PROS, conditions. All of the people in the study had a PIK3CA mutation confirmed by their doctor.

People experienced a reduction in the size of overgrowths

27% (10 of 37) of people taking VIJOICE saw their overgrowth shrink by at least 20% in 6 months. These people had scans to confirm their reductions of at least 20%. The reductions had to be seen in at least 2 scans in a row to be confirmed. Two additional people saw their overgrowth shrink by at least 20%, but these reductions were not confirmed in a second scan

People maintained a reduction of at least 20% in the size of their overgrowths

Durable reduction

Reductions were maintained for at least 6 months in 70% of people

 

Reductions were maintained for at least 12 months in 60% of people

74.2% (23 of 31) of people taking VIJOICE saw any shrinkage in the size of their overgrowth. Thirty-one people who had their overgrowth assessed by scans at 6 months were included in this analysis

 

People reported functional improvement

Approximately 30% (14 of 47) of people taking VIJOICE saw improvements in their ability to do things

of people taking VIJOICE saw improvements in their ability to do things

Two scales were used to measure a person’s functional improvement.
The first scale measured a person’s daily activity, physical ability, and ability to care for themselves. An improvement was defined as a decrease by at least 1 point, and worsening was defined as an increase by at least 1 point.
The second scale measured a person’s ability to perform normal activities of daily living and functional status. An improvement was defined as an increase by at least 20 points, and worsening was defined as a decrease by at least 20 points.

 

People experienced an improvement in PROS signs and features

In 6 months:

List of the ways VIJOICE improved common PROS symptoms in children and adults.
CLOVES, congenital lipomatous overgrowth, vascular malformations, epidermal nevi, scoliosis/skeletal and spinal; MCAP or M-CM, megalencephaly-capillary malformation; KTS, Klippel-Trenaunay syndrome; FIL, facial infiltrating lipomatosis.